Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.
about
Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniaePrevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitisDaptomycin in experimental murine pneumococcal meningitis.Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitisPenetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Attenuation of cognitive impairment by the nonbacteriolytic antibiotic daptomycin in Wistar rats submitted to pneumococcal meningitis.Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections.A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections.Treatment and prevention strategies to combat pediatric pneumococcal meningitis.Update on daptomycin: the first approved lipopeptide antibiotic.Current concepts in the treatment of bacterial meningitis beyond the neonatal period.Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections.Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.Pre-clinical experience with daptomycin.Emerging drugs for acute bacterial meningitis.Acute bacterial meningitis in infants and children: epidemiology and management.Bacterial meningitis: current therapy and possible future treatment options.Treatment of bacterial meningitis: an update.Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Bacterial meningitis: new therapeutic approaches.Treatment strategies for central nervous system infections: an update.Bacterial meningitis: insights into pathogenesis and evaluation of new treatment options: a perspective from experimental studies.Bacterial meningitis: an update of new treatment options.Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.Daptomycin versus vancomycin in treatment of methicillin-resistant Staphylococcus aureus meningitis in an experimental rabbit modelCombination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone.Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: high-dose and combination daptomycin therapy.Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid.Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.Successful treatment of methicillin-resistant staphylococcus aureus meningitis with daptomycin.
P2860
Q24656785-E6B6DE2F-6B9B-4437-981B-3F441C4FCFC6Q28757559-7633594C-AB30-4F04-AB58-8776C77C7279Q33437256-E679DE33-1C80-43DC-B5ED-68CB8DC7C706Q33676211-22B23E8F-B604-4600-85D2-C17919571B2DQ34142328-E21FE4BD-D174-4E26-9729-4C3F355048B7Q34157657-DA8B5D39-0607-4B1A-88F0-1558CF4A234AQ34645552-3D2B9B1E-B9BC-4599-8065-5A172576F74FQ35065838-5F14E493-9ED7-4D1E-8D19-3802616C78D9Q35166807-EB832D1E-B80C-4B2B-AD8A-FADFAACA4C04Q36278050-411E2997-8F02-443F-8185-2CCE253951D0Q36521880-67A23D0D-74B4-4C47-B5B9-4DDE2A13FAAAQ36607421-32C55A9C-B88D-43E7-97F3-856AA81CCA0BQ36777821-14A55664-CAC7-4316-8443-C8551863086DQ36777850-54D78545-66B4-4A5F-95EB-AC3E70B323B2Q37077629-E98C9EA1-413C-4D44-9CB0-DF517E38A03EQ37284356-F6262620-1582-4360-B50A-B8E3C7E1DFAEQ37558543-0D91EEAD-A123-4CFC-84DB-2A19EBD08E4FQ37945754-238BE6C5-C5C9-4377-B0AC-A6FCE93E14B6Q37949641-8B4CBF77-F239-4D87-9579-CA6AC06B94F0Q38044024-2D0FAD44-E38E-41E2-81B8-118F4D187956Q38100704-1A60399B-715E-42F0-9A6C-00983ECC726DQ38145360-305EA8DF-6CC6-48A8-9A0A-D4F47557DDA6Q38261298-D41E67C8-5E0E-4F8C-8416-4484BA9AD770Q38539643-E0EA1571-4CC3-4D39-BCC2-2D19550C8AB9Q38570487-AFF1B61C-1C43-4082-8BCA-CCF21494E19BQ40189196-B3B100DA-91BB-43FA-A6B1-40E180793203Q41451653-D77161E7-56D6-4CDF-81E7-25A3E44554EEQ41873974-BFB26A76-8E3B-44A5-9CE0-5DB8F0F02D3BQ42747682-EDF9096D-7EE3-4FFD-AD8D-FAC7D3D1D601Q42789679-F6E828ED-8E1B-4A6A-80F6-0555C1028597Q42854012-9F2549B9-9922-482A-A427-8976F14888E8Q43183404-D523EF98-30C1-47D5-A2C3-81F8500FAE87Q46274310-F247656F-6A2F-4B6E-8AA0-FA5799E71404Q46476420-5B664009-E10E-4527-9540-206008D721B2
P2860
Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Daptomycin is highly efficacio ...... ci in experimental meningitis.
@en
type
label
Daptomycin is highly efficacio ...... ci in experimental meningitis.
@en
prefLabel
Daptomycin is highly efficacio ...... ci in experimental meningitis.
@en
P2093
P2860
P1476
Daptomycin is highly efficacio ...... ci in experimental meningitis.
@en
P2093
Armin Stucki
Felix Kühn
Fernando Acosta
Hans-Peter Müller
Lukas Flatz
Marc Pfister
Marianne Cottagnoud
Philippe Cottagnoud
P2860
P304
P356
10.1128/AAC.48.10.3928-3933.2004
P407
P577
2004-10-01T00:00:00Z